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Introduction: Ramadan is a holy month and the majority of Muslims fast in it, without considering background 
illnesses. SGLT-2 drugs were available for Pakistani patients recently, and this was the first year to fast in their 
presence. 
 
Objectives: To assess the risk of hypoglycemia in fasting diabetics using SGLT-2 drugs, comparing it with 
Sulphonylurea (SU) drugs. Also, a change in HbA1c and eGFR was checked. Hence, evidence was collected to 
recommend their use in fasting Diabetics with safety.   
 
Material and Methods: A total of 5500 patients from three different sites were included. Only 500 fulfilled the 
criteria of inclusion. Pregnant, lactating, advanced Chronic Kidney Disease (CKD), and those recording 
hypoglycemia frequently were not included. Ages between 20 to 70 years, HbA1c between 7 to 11, and patients 
taking SU or SGLT-2 were included.  
 
Conclusion: The eGFR was comparable in both groups post-Ramadan. HbA1c was significantly reduced in the 
SGLT-2 group. Bitter taste and thirst were common with the SU group. Hypoglycemia was comparable in both 
groups. We concluded that SGLT-2 drugs were safe during Ramadan, and caused more HbA1c reduction.  
 
Keywords: Safety, Fasting, Hypoglycemia, SU, Sodium-Glucose Co-transporter. 
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Introduction 
 
Ramadan is a holy month, where the majority of 
Muslims prefer to fast, despite odds. It included 
abstinence from eating or drinking from dawn to dusk. 
Behavior was similar in diabetics, keen to take 
chances.1 In recent years, a new group of drugs called 
SGLT-2 was introduced for diabetic patients, with not 
much evidence available in fasting. In Pakistan, these 
medicines were officially launched at the end of the 
first half of 2018; therefore local evidence was limited 
for them.2  
There were few groups of medicines used by diabetics 
that did not cause hypoglycemia. SGLT-2 drugs 
belonged to the same, with a mechanism not 
promoting change in body insulin, rather increased 
excretion of glucose from urine, causing water loss 
along with it. This can be caution in fasting, because of 
extreme temperatures in Pakistan, especially in 
summers.3  
In previous literature, EPIDIAR study4 showed that 
there was a 7.5% increased risk of hypoglycemia in 
patients who wanted to fast. It showed the importance 
of hypoglycemia as the single most important 
complication of fasting diabetics. In VECTOR study5, 
comparing SU with Dipeptidyl Peptidase-4 (DPP-4) 
Inhibitors, it was concluded that 41.7% of patients on 
SU had hypoglycemia.  
Shoa Y et al carried out a study on SGLT-2 in 
Singapore on patients with similar characteristics. 
They concluded that fasting led to significant blood 
pressure and weight reduction, but did not increase 
the risk of ketonemia. It was carried out in a small 
population of 68 patients. Moreover, it did not check 
for HbA1c, eGFR, and hypoglycemia details in these 
patients.6 
Alaaeldin Bashier et al studied patients on SGLT-2 
drugs in different combinations in Dubai, observing 
for hypoglycemia. Hypoglycemia was frequent when 
Insulin was combined with SGLT-2. It was less 
common when basal insulin or any oral agent 
including SU was combined. The observation was that 
weight and HbA1c were reduced significantly, but 
there was no change in renal function or lipid profile. 
We conducted a different study. Our patients were 
using oral medicine only. We compared with SU, 
known to cause hypoglycemia, keeping euglycemic 
medicine like DPP4 or Metformin common.7 
W.J. Wan Seman et al compared SU drugs with 
Dapagliflozin, on 110 patients. They either continued 
them on SU, or changed them to Dapagliflozin, and 
observed hypoglycemia and postural hypotension 
during Ramadan. More significant hypoglycemia was 
present in the SU group with no change in postural 
blood pressure documented. Our study also compared 
SU and SGLT-2, with a bigger pool. We also checked 
for a change in HbA1c, eGFR, and Hypoglycemia. The 
topic was not widely published from this region.8 
Hence, we aimed to assess hypoglycemia in fasting 
diabetics using SGLT-2 drugs and compared it with 
SU, before, during, and after Ramadan. We also 
checked for a change in HbA1c and eGFR. In this way, 
we collected evidence to recommend their safe use.   
 
Materials and Methods 
 
Data of 500 patients were selected from three different 
sites. Total 2500 patients from site one and 1500 each 
from site two and three were initially assessed, making 
the total screened patients 5500. After consent, those 
who were taking medicines for 6 weeks were included. 
Medicine was continued as previous from personal 
resources, with dose adjustment if required. Patients 
on additional medicine like Metformin, DPP-4, or a 
combination of them, were continued as such. 
Patients were contacted twice during the study period 
after induction. After consent, initial interaction, and 
assessment before Ramadan, they were asked 
questions second and third times during and after 
Ramadan. HbA1c and creatinine were recorded at the 
start and the conclusion after 12 weeks. Also, if the 
patients experienced any problem, they were 
instructed to contact the calling doctor from the 
research team. 
For checking blood sugar levels, guidelines from IDF 
were followed, regarding diabetes and Ramadan.9 
They recommend that every high and very high-risk 
patient should check up to 6 times a day. It was only 
intended to follow these instructions in very high and 
high-risk groups. Moderate and low-risk patients were 
relaxed. If hypoglycemic episodes were frequent or 




It was an open-labeled, randomized, two arms, the 
non-inferiority study was conducted over 12 weeks, 
from 1 April 2019 to 30 June 2019. The response of 
patients related to the effects of SGLT-2 inhibitors and 
SU were observed in relation to hypoglycemia before, 
during, and after Ramadan. The mean age was 
50.40±10.75 years. Minimum was 18 years and 
maximum, 85 years. Total 222 were taking SU, and 279 
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SGLT-2. The mean age in SU was 50±11 years, 
minimum 23 and maximum 80 years. The mean age of 
SGLT-2 was 51±11 years with a minimum of 18 and a 
maximum of 85 years. The majority were between 30-
50 years, followed by more than 50 years. The chi-
square value was 1.145 and the p-value 0.564. The 
proportion of males taking SGLT-2 was greater than 
the females when compared with the SU group. It was 
57.9 females in SU, and 42.1 males (chi-square= 0.469, 
p-value= 0.493) (Table 1).  
The obesity index of patients was quite high with the 
majority having BMI greater than 30 (chi-
square=13.316, p-value=0.004). A large proportion had 
blood pressure readings within the normal range 
when included (chi-square=5.483, p-value=0.241). The 
majority reported that the duration of diabetes was 
less than five years (chi square=1.309, p-value=0.520). 
On the assessment of complications, the incidence of 
dyslipidemia higher in the SGLT-2 than in the SU 
group (chi square=0.233, p-value=0.629). Nephropathy 
(chi square=0.044, p-value=0.834) and retinopathy 
were more in SGLT-2 than SU (chi square=1.236, p-
value=0.266). Neuropathy was 24.2% and 34.6%, more 
in SU group (chi square=4.253, p-value=0.039). 
Patients on SU had more macro-vascular 
complications like CVA, CVD, and PVD than SGLT-2 
(Table1).  
The majority of patients on SGLT-2 had CKD stage 2. 
Similar trend was noticed in post-Ramadan readings 
(chi-square=5.900, p-value=0.117). HbA1c of majority 
of patients before Ramadan was >9 (chi-square=1.635, 
p-value=0.651) with slightly more in SGLT-2 group. 
This trend improved after Ramadan. It fell to 7.5-9 
range in both groups (chi-square=2.202, p-
value=0.332), but more in SGLT-2 group.  
Figures 1, 2, and 3 compared the response of patients 
regarding hypoglycemia before, during, and after 
Ramadan. Proportion of patients experiencing 
hypoglycemia before Ramadan in SGLT-2 and SU 
group was 90.9% and 83.3% respectively (chi-
square=6.040, p-value=0.014), but during Ramadan it 
was only 8.2% and 10.7% (chi-square=0.856, p-
value=0.355). After Ramadan incidence decreased 
further with 6.7% and 7.4% in both groups (chi-
square=5.012, p-value=0.082). Patients experiencing 
symptomatic hypoglycemia before Ramadan (chi-
square=6.178, p-value=.046) was almost equal to those 
experiencing symptoms during Ramadan (chi-
square=0.799, p-value=0.372). It indicated that patients 
were unaware to check BSR level when they 
experienced hypoglycemia during fast. More patients 
on SGLT-2 required assistance and/or admission 
during event of hypoglycemia (chi-square=0.582, p-
value=0.446), but after Ramadan it was greater in the 
SU group (chi-square=0.528, p-value=0.468), and 
patient required assistance during Ramadan (chi-
square=1.049, p-value=0.592). Patients documenting 
low BSR without symptoms were equal in both groups 
before Ramadan and more with SGLT-2 during and 
after Ramadan. It showed that patients taking SGLT-2 
were more aware of treating symptoms of 
hypoglycemia before and during Ramadan. After 
Ramadan, 17.8% of patients in the SU and 12.8% in the 
SGLT-2 were aware of treating low BSR without 
symptoms. The incidence of feeling more thirst during 
fast and bitter taste in the mouth was more in the SU 
as compared to the SGLT-2 group. 
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 30-50 73.5% 75.5% 
>50 25.6% 22.7% 
GENDER 
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0.266 




YES 24.2% 32.6% 4.253 
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0.834 
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0.718 
 NO 98.2% 98.6% 
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 NO 99.1% 98.2% 
PVD YES 13.7% 20.6% 4.017 0.045 
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CKD STAGE1 33.9% 48.7% 9.541 
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 CKD STAGE2 40.2% 37% 
CKD STAGE3a 24.9% 10.9% 
CKD STAGE3b 1.8% 3.4% 
CKD STAGE4 0.0% 0.0% 
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6.5-7.5 17.2% 16.6% 2.202 0.332 
7.5-9 50.0% 42.4% 












Figure: 3 Comparison of Hypoglycemia of 






Different characteristics in both groups were 
compared. According to age, the majority were 
between 30-50 years. The possible reason could be that 
this age group roams independently, hence the easy 
approach to the hospital. Our center was a tertiary care 
center, situated on the first floor. This could be another 
difficulty for middle-aged and elderly patients. 
Females were more in attendance. The reason could 
center timings between 8 to 2 PM, with difficulty for 
working class. We also know that long waiting hours 
in the public sector make it difficult for most patients. 
Benner et al10 have compared the age difference in 
their study, with a 10-year group difference. Their 
findings were different probably due to available 
resources in Turkey and age difference. 
Aydin et al11 carried out a meta-analysis to ascertain 
the effects of Ramadan fasting on HbA1c, postprandial 
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glucose, fasting glucose, Body mass index (BMI), and 
fructosamine levels. They concluded that the use of 
single or multiple medications in Ramadan did not 
affect postprandial and fructosamine levels, but it had 
beneficial effects on BMI, Fasting Glucose, and HbA1c. 
The majority of overweight patients in our study were 
on SGLT-2, but the obese category was more in SU 
(SU). This could be incidental, but one explanation 
was that intake of SU for a longer period tends to 
increase weight. Our SGLT-2 patients were overweight 
or obese. However, we noticed that there were more 
obese patients in the SU group.  
Shao et al12 have already published that the blood 
pressure-lowering effect was well known with SGLT-2 
drugs during Ramadan fasting. Why our patients 
showed higher blood pressure in stages 2 and 3 at the 
time of induction before Ramadan? We cannot justify 
it. A probable reason could be patient selection bias. 
On the other hand, why were normotensives more in 
the SGLT-2 group, we could not explain to satisfaction. 
It could be just by chance. The majority of our patient's 
diabetes duration was less than 5 years, suggesting 
that patients reported here early with the disease. 
Also, there were a large group of patients on newer 
drugs like SGLT-2, showing that our healthcare 
professionals had adequate knowledge on starting a 
new medicine, and were confident users. 
Almalki and Alshahrani13 et al have concluded that 
complications like hypoglycemia, hyperglycemia, and 
lifestyle change should be addressed to minimize 
complications.  In our study, we found that 
Dyslipidemia and Nephropathy were equal in the 
distribution in both groups. Reasons were not known 
to us. We need more local evidence on this. 
Retinopathy and Cerebrovascular disease were more 
in the SGLT-2 group. Similarly, neuropathy, 
cardiovascular disease, and peripheral vascular 
disease were more in the SU group. Neuropathy is 
microvascular and develops early, whereas the other 
two develop late. Why were these differences between 
the two groups? An explanation could be just by 
chance, and we require more local evidence to find out 
the reason.  
Bener et al10 documented that fasting had a significant 
beneficial effect on HbA1c reduction, but the effect on 
creatinine was not statistically significant. When 
comparing eGFR for pre and Post-Ramadan, we found 
that except for CKD stage 2 and 3a, the rest of the 
values were higher in the SU group, with the p-value 
insignificant. There was decreased in both these stages 
for SGLT-2 after Ramadan, suggesting no adverse 
effects of fasting with SGLT-2.  We recommend more 
studies to support these findings. For the HbA1c 
comparison of pre and Post-Ramadan groups, there 
was a significant reduction in the SGLT-2 group 
having HbA1c more than 9%. The rise was noted in 
the group between 7.5 and 9%. It suggested that the 
higher the HbA1c more was positive responses during 
fasting. However, further studies were needed to 
validate our findings.  
Raveendran and Zargar et al14 have documented that 
fasting in diabetics can pose a medical challenge to 
both patients and health care professionals, and with 
proper guidance, risks can be reduced. The most 
important part of our study was to assess the 
hypoglycemic effects of these medications in 
comparison, before, during, and after Ramadan. Six 
questions were asked in all three periods. First, 
whether they experienced any hypoglycemic 
symptoms? Second, did they note blood sugar levels at 
that time, and what was it? Third and fourth, if they 
were able to self-treat or required assistance. Fifth, if 
they had asymptomatic hypoglycemia, and finally, if 
they felt and treated hypoglycemia without checking.  
Mansouri et al15 carried out a study on self-monitoring 
of blood sugar during Ramadan. They concluded that 
sugar levels fluctuated with age, and with better 
understanding and change in lifestyle, fasting can be 
made safe. In our study, hypoglycemia was higher in 
the SGLT-2 group before Ramadan, which decreased 
significantly during and after, as compared to the SU 
group. We cannot justify the reason, but maybe due to 
discipline during Ramadan, conscious about 
hypoglycemia with a new drug, and checking it more 
frequently.  
Aldawi et al16 carried out a study, comparing glucose 
excursions during fasting with Continuous Glucose 
Monitoring (CGM) device. They concluded that there 
was not much difference before, during, or after 
Ramadan when using oral drugs, except Insulin and 
SU drugs. In our study regarding checking blood 
sugar levels when symptomatic hypoglycemia, it was 
noted that the SU group had more frequency before 
Ramadan in all three periods and kept on decreasing. 
The reason could be dose change, diet composition, 
discipline about diet, and intake of high caloric food 
with delayed-release during Ramadan. We need more 
studies on the composition of a diet to support our 
justification.  
Lee et al17 compared two groups for hypoglycemia, 
using telemedicine monitored sugar levels with a 
control group. They documented significantly better 
results for the telemedicine group in symptoms and 
HbA1c at completion. In our study self-treatment of 
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hypoglycemia, SU group was more frequent before, 
with a decrease seen during, and significant fall in 
post-Ramadan period. However, the frequency was 
higher in the SGLT-2 group Post-Ramadan. The reason 
could be that patients were more conscious about 
hypoglycemia during Ramadan and were confident in 
the Post-Ramadan period regarding managing their 
diabetes, resulting in better responses. However, we 
could not explain why the SGLT-2 group had a higher 
frequency in the Post-Ramadan period. A probable 
reason could be the careless attitude of patients in this 
group regarding intake of diet. We need more studies 
to find out the exact levels which were treated as 
hypoglycemia.  
Hassanein et al18 compared two different insulins for 
safety in Ramadan. They concluded that less 
hypoglycemia and/or assistance was required when 
new insulin degludec/insulin aspart (IDegAsp) was 
used. We had used oral medicines for safety 
comparison. Regarding assistance for hypoglycemia, 
the SGLT-2 group required more assistance before 
Ramadan. Being a euglycemic medicine, it was not 
expected, and the possible reason could be anything 
from lifestyle to concomitant medicine intake. There 
was no difference between the two groups during 
Ramadan. Post-Ramadan minor difference was more 
frequent in the SU group, which was already 
anticipated. 
Badshah et al19 reviewed multiple articles and 
documented that hypoglycemia was a very 
challenging complication in Ramadan. In our study, 
we found that asymptomatic patients could also have 
hypoglycemia. The frequency was higher in the SGLT-
2 group in the Pre-Ramadan period. It decreased 
during and Post-Ramadan period, but still higher in 
the SGLT-2 group. Our expectation was otherwise. SU 
group was more likely to cause hypoglycemia. 
Justification could lie in the half-life of SGLT-2 drugs, 
long duration of fast and possible changes in lifestyle, 
which were not checked here. We, therefore, suggest 
more randomized trials.  
Elhadd et al20 studied fasting diabetics using multiple 
drugs. They found more hypoglycemic episodes with 
increasing medicine and suggested simpler regimens 
for Ramadan. We found that symptomatic non-
documented hypoglycemia patients were quite a few. 
SGLT-2 group had more frequency in pre and during 
Ramadan period, but Post-Ramadan it was higher in 
SU group. It was expected that SU group patients were 
more likely to suffer from symptomatic hypoglycemia 
than the SGLT-2 group, but why was it different 
before and during Ramadan? The reason could be in 
the frequency of monitoring and confidence of 
patients. More studies were needed to assess this 
behavior.  
Mudher Mikhael et al3 studied the safety of new drugs 
in Ramadan, documenting increased thirst sensation 
as a side effect of SGLT-2 drugs. Since SGLT-2 drugs 
were known to lose water from the body, we checked 
if they caused thirst and bitter taste, and found that 
both symptoms were more with the SU group. The 
bitter taste can be explained, but why increased thirst 
with SU? A possible reason could be poor glycemic 
control, leading to increased urine frequency. Since we 
have not documented urine frequency, we would 




The majority of our patients attending clinics were 
between 30-50 years of age, with predominant females. 
Most of the patients also had a duration of fewer than 
5 years, and patients of obesity and overweight were 
comparable in both groups. Micro and macrovascular 
complications were present on both sides. CKD stage 2 
and 3a were present more with the SGLT-2 group and 
showed improvement during and after Ramadan, 
suggesting it was safe during fast. HbA1c was higher 
at the start in both the groups and improved more 
significantly in the SGLT-2 group. Bitter taste and 
thirst were more common with the SU group. 
Hypoglycemia was comparable in both groups. We 
concluded that SGLT-2 drugs were safe for fasting 




First, both groups were not matched completely. The 
numbers of patients were also different. Results could 
be different if it was taken care off. Second, we did not 
record the number of days fasted by the individual but 
was inquired if they had a total of 20 days or more 
fasting. It was therefore not mentioned in the 
methodology. Third, all study period was majority 
carried out on telephone questions, with only 2 visits 
at the induction and conclusion. We may find it 
different if patients were physically present at the time 
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